Study for the Treatment of Ulcerative Colitis With Adacolumn

Key Inclusion Criteria: * Moderate to severe active ulcerative colitis with colonic involvement with ulcerative colitis beyond 15 cm of the anal verge * Adequate peripheral venous access to allow for completion of the apheresis treatments * Receiving one or more of the following medical therapies: \*sulfasalazine, \*mesalamine and other 5-ASA agents, \*prednisone or 6-mercaptopurine or azathioprine OR Have not received the above medical therapies due to intolerance or demonstrated non-response * Agree to participate in the required follow-up visits * Able to complete a diary * Signed written informed consent document and authorization for use of protected health information Key Exclusion Criteria: * Evidence of toxic megacolon * Major surgery within the past 6 weeks or anticipated need for surgery within 12 weeks * Proctocolectomy, total colectomy, ileostomy, stoma or ileal pouch-anal anastomosis * Requiring in-patient hospitalization * A history of allergic reaction to heparin or heparin-induced thrombocytopenia * A history of hypersensitivity reaction associated with an apheresis procedure or intolerance of apheresis procedures * A history of severe cardiovascular or peripheral arterial diseases * A history of cerebral vascular diseases * Liver diseases * Renal insufficiency * Insulin-dependent Type I or Type II diabetes * Known bleeding disorder or use of concomitant anticoagulant therapy for purposes other than apheresis treatment * Any hypercoagulable disorder * Known infection with Hepatitis B or C, or HIV * Severe anemia * Leukopenia or granulocytopenia * Evidence of current systemic infection * Malignancy * Pregnant, lactating or planning to become pregnant during the course of the investigational study * Used within the last 30 days, an investigational drug, biologic or device or 5 half-lives, if known, for any investigational drug or biologic